Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19(+) malignancy

Current Food and Drug Administration (FDA)-approved CD19-specific chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies are constitutively active and while efficacious, can cause morbidity and mortality. Their toxicities might be reduced if CAR T-cell activity was regulatable rath...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennell, Christopher A, Campbell, Heather, Storlie, Meghan D, Bolivar-Wagers, Sara, Osborn, Mark J, Refaeli, Yosef, Jensen, Michael, Viaud, Sophie, Young, Travis S, Blazar, Bruce R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756162/
https://www.ncbi.nlm.nih.gov/pubmed/36521930
http://dx.doi.org/10.1136/jitc-2022-005934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756162/
https://www.ncbi.nlm.nih.gov/pubmed/36521930
http://dx.doi.org/10.1136/jitc-2022-005934

Ejemplares similares